Generali Investments Management Co LLC has significantly increased its investment in Gilead Sciences, Inc. (NASDAQ: GILD) by 44.8% during the third quarter of 2023. According to its latest 13F filing with the Securities and Exchange Commission, the firm now holds a total of 19,605 shares after acquiring an additional 6,067 shares, valuing its stake at approximately $2.18 million at the end of the quarter.
This move follows a broader trend among institutional investors, with several firms adjusting their positions in Gilead Sciences. Vanguard Group Inc., for instance, raised its stake by 1.6% in the second quarter, now owning 119,364,226 shares worth around $13.23 billion. Similarly, Geode Capital Management LLC increased its holdings by 2.6%, bringing its total to 29,207,662 shares valued at approximately $3.23 billion. Other notable investors include Norges Bank, which established a new position valued at $2.15 billion, and Invesco Ltd., which grew its holdings by 33.5% to 13,521,228 shares worth $1.50 billion.
Institutional investors collectively own about 83.67% of Gilead’s shares, reflecting strong confidence in the company’s market potential.
Stock Performance and Dividend Increase
As of the latest trading session, shares of Gilead Sciences opened at $143.77. The company maintains a debt-to-equity ratio of 0.98, with a quick ratio of 1.31 and a current ratio of 1.55. Recent performance indicators show the stock has a 50-day moving average price of $135.61 and a 200-day moving average price of $124.58. Gilead Sciences currently boasts a market capitalization of $178.48 billion, a price-to-earnings (PE) ratio of 21.24, and a price-to-earnings-growth (PEG) ratio of 1.93. The stock has fluctuated between a 52-week low of $93.37 and a high of $157.29.
In addition to its stock performance, Gilead Sciences announced a quarterly dividend of $0.82 per share, set to be paid on March 30, 2024. This marks an increase from the previous quarterly dividend of $0.79, resulting in an annualized dividend of $3.28 and a yield of 2.3%. The ex-dividend date is March 13, 2024.
Analyst Ratings and Insider Activity
Recent assessments from financial analysts reflect a generally positive outlook for Gilead Sciences. Rothschild & Co Redburn raised their price target for the stock from $159.00 to $170.00, maintaining a “buy” rating. Similarly, JPMorgan Chase & Co. increased its target from $150.00 to $160.00, assigning an “overweight” rating. Analysts from UBS Group, Wolfe Research, and Truist Financial have also issued optimistic projections, contributing to a consensus rating of “Moderate Buy” on MarketBeat.com, with an average price target of $156.72.
On the insider front, Daniel Patrick O’Day, CEO of Gilead Sciences, sold 115,640 shares on January 23, 2024, for a total value of $15,611,400. Following this transaction, he retains 566,698 shares valued at approximately $76.50 million. Additionally, Jeffrey Bluestone, a director at Gilead, sold 5,000 shares on January 20, 2024, at an average price of $123.50, totaling $617,500. Insiders collectively sold 299,280 shares valued at $42.49 million over the past three months, indicating a modest reduction in their ownership, as company insiders now hold 0.27% of the stock.
Founded in 1987 and headquartered in Foster City, California, Gilead Sciences focuses on developing and commercializing medicines for areas with significant unmet medical needs. The company’s portfolio includes antiviral therapies for HIV and hepatitis, as well as treatments for oncology, cell therapy, and inflammatory diseases.
